drugset / Trial / NCT04030988
Contribution of Skin Color in Stabilization of Active Cases of Vitiligo by Narrow Band UVB
Phase 1
Unknown
100 enrolled
Ain Shams University
Alexandria University · collabAssiut University · collabCairo University · collabMenia University · collabSuez Canal University · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
Vitiligo is a disease in which autoimmunity plays a major role. Multiple treatment options are available, of which narrow-band UVB is a cornerstone, acting through immunosuppression and repigmentation by stimulating reservoir melanocytes. It's expected that this immunsupression is lower in darker skin types, where increased basal melanin might act as a barrier.
Timeline
- Start
- 2018-11-01
- Primary completion
- 2019-09
- Completion
- 2019-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Dexamethasone | Small molecule | 1.5 mg | Oral |
| Comparator | Dexamethasone | Small molecule | 3 mg | Oral |